Treating Patients with Myelodysplastic Syndrome and IDH or TP53 Mutations


Eytan M. Stein, MD, discusses how to treat patients with MDS who have IDH or TP53 mutations, and whether there is a role for targeted therapy in this patient population.

Related Videos
Video 7 - "Unmet Needs and Future Directions in HER2+ Breast Cancer"
Video 6 - "Current Approaches to Treatment Sequencing in HER2+ Breast Cancer"
Video 5 - "Exciting Developments in HER2+ Breast Cancer"
Related Content